Original article
The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis
Seguridad y eficacia de tolvaptan en el tratamiento de los pacientes con enfermedad renal poliquística autosómica dominante: Revisión sistemática y metaanálisis
a Division of Nephrology, The First College of Clinical Medical Science, Three Gorges University, Yichang, Hubei, China
b Division of Endocrinology, The Renhe Hospital of Three Gorges University, Yichang, Hubei, China
c Division of Urinary Surgery, The First College of Clinical Medical Science, Three Gorges University , Yichang, Hubei, China
Read
8373
Timeswas read the article
2111
Total PDF
6262
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 11 | 310 | 59 | 369 |
| 2025 10 | 260 | 74 | 334 |
| 2025 9 | 224 | 84 | 308 |
| 2025 8 | 145 | 79 | 224 |
| 2025 7 | 168 | 60 | 228 |
| 2025 6 | 226 | 132 | 358 |
| 2025 5 | 167 | 46 | 213 |
| 2025 4 | 165 | 39 | 204 |
| 2025 3 | 150 | 78 | 228 |
| 2025 2 | 144 | 41 | 185 |
| 2025 1 | 153 | 41 | 194 |
| 2024 12 | 102 | 40 | 142 |
| 2024 11 | 95 | 65 | 160 |
| 2024 10 | 124 | 57 | 181 |
| 2024 9 | 105 | 48 | 153 |
| 2024 8 | 125 | 91 | 216 |
| 2024 7 | 130 | 47 | 177 |
| 2024 6 | 149 | 42 | 191 |
| 2024 5 | 159 | 55 | 214 |
| 2024 4 | 147 | 51 | 198 |
| 2024 3 | 157 | 35 | 192 |
| 2024 2 | 100 | 44 | 144 |
| 2024 1 | 84 | 31 | 115 |
| 2023 12 | 162 | 41 | 203 |
| 2023 11 | 134 | 57 | 191 |
| 2023 10 | 122 | 50 | 172 |
| 2023 9 | 366 | 33 | 399 |
| 2023 8 | 429 | 25 | 454 |
| 2023 7 | 434 | 31 | 465 |
| 2023 6 | 177 | 28 | 205 |
| 2023 5 | 150 | 69 | 219 |
| 2023 4 | 105 | 40 | 145 |
| 2023 3 | 89 | 57 | 146 |
| 2023 2 | 73 | 49 | 122 |
| 2023 1 | 70 | 46 | 116 |
| 2022 12 | 95 | 46 | 141 |
| 2022 11 | 111 | 78 | 189 |
| 2022 10 | 156 | 122 | 278 |
Show all
